ArticleFrontiers in medicine2026
Retrospective analysis of clinical efficacy and safety of fluorometholone combined with azelastine eye drops for seasonal allergic conjunctivitis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Seasonal allergic conjunctivitis (SAC) is a common ocular allergic disease, predominantly affecting children and young adults, with no significant gender predominance. Aim: This study aimed to retrospectively evaluate the clinical efficacy and safety of fluorometholone combined with azelastine eye drops versus azelastine monotherapy in patients with SAC. Methods: This single-center retrospective study enrolled 180 SAC patients from January 2022 to June 2024. Patients were divided into a combination group (fluorometholone 0.1% QID + azelastine 0.05% BID, Results: The combination group showed significantly greater reduction in symptom and sign scores from week 1 onward ( Conclusion: Fluorometholone combined with azelastine is more effective than azelastine monotherapy in treating SAC, providing faster symptom relief, higher efficacy, lower recurrence, and a comparable safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.